Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Kiesha Wilson · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · 2023 · $62,501 — PROJECT SUMMARY/ABSTRACT The virus, SARS-CoV-2 has caused COVID-19 and claimed the lives of over 240,000 Americans and 1,270,000 people worldwide. Severe cases of the disease leads to Acute Respiratory Distress Syndrome (ARDS), sepsis and can be fatal due to pulmonary inflammation and destruction of…
Franklin Caval-Holme · BOSTON CHILDREN'S HOSPITAL · 2023 · $69,500 — PROJECT SUMMARY/ABSTRACT When faced with a visual scene, the brain encodes both image detail and the scene’s overall intensity, measured as irradiance. Encoding irradiance is critical for circadian regulation, pupil constriction, and image vision, among other important functions. A canonical feature…
Andrew Laurence Routh · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $171,291 — RNA viruses are exceptionally diverse and rapidly evolving. Their RNA-dependent RNA polymerases are prone to mutation, lack proof-reading capabilities (with the unique exception of coronaviruses) and frequently undergo recombination between both homologous and non-homologous templates. This confers …
Mark L Baccei · UNIVERSITY OF CINCINNATI · 2023 · $606,669 — Project Summary/Abstract Long-term potentiation (LTP) of primary afferent synapses onto spinal projection neurons (PNs) has been linked to increased pain sensitivity. The timing rules controlling the generation of LTP in adult PNs can be persistently relaxed by neonatal tissue damage, which likely …
Rongsheng Jin · TUFTS UNIVERSITY BOSTON · 2023 · $865,682 — ABSTRACT In previous NIH sponsored research we successfully tested the hypothesis that integrating structural and mechanistic information into heteromultimeric VHH-based neutralizing agent (VNA) design facilitated development of antitoxins with even greater efficacy and versatility. In this renewal …
Vijaya Mohan Rao Lella · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · 2023 · $220,500 — Emerging evidence indicates that the novel SARS-CoV-2 infection is associated with a high incidence of thrombotic complications. Thrombotic complications in COVID-19 patients are found to be life-threatening. Elevated D-dimers and disseminated intravascular coagulation (DIC) are strong predictors of…
Alexander Dickson · MICHIGAN STATE UNIVERSITY · 2023 · $327,537 — Project Summary Biology at the nanoscale is driven by molecular recognition. Cells are lined with receptors that recognize a myriad of biomolecules and transmit signals to the cell interior. This forms the basis of cell-cell communication that allows multicellular organisms to thrive. An understandi…
Houjian Cai · UNIVERSITY OF GEORGIA · 2023 · $188,750 — Summary/Abstract SARS-CoV-2 has infected over 51 million and is responsible for the death of over 1.27 million people globally. Interventions to address both prevention and treatment are urgently needed. Infection of SARS-CoV- 2 requires the host serine protease TMPRSS2 to activate the virus spike p…
Paul John Norman · UNIVERSITY OF COLORADO DENVER · 2023 · $714,601 — Summary To ensure a successful and sustained response to the COVID-19 crisis it becomes imperative that the functional implications of the considerable genotypic and phenotypic variation in natural human immunity are understood. Natural killer (NK) cells have major roles in controlling the innate an…
JOEL N BLANKSON · JOHNS HOPKINS UNIVERSITY · 2023 · $204,688 — Project Summary Two mRNA COVID vaccines that have greater than 90% efficacy in healthy donors have been developed. However the efficacy of these vaccines in PLWH is unknown. PLWH have had suboptimal responses to some prior vaccines potentially because they make limited naïve T cell responses. We and…
Thomas M McIntyre · CLEVELAND CLINIC LERNER COM-CWRU · 2023 · $572,341 — Hypertension, for unknown reasons, is a primary co-morbidity risk factor for poor COVID-19 outcomes. SARS- Cov-2 breaches the lung blood-air barrier to spread among organs inducing endothelial cell dysfunction and multi-organ thromboembolism. ACE2 is the high affinity receptor for SARS-Cov-2 with TM…
Maria Cristina Gingerich · CYANVAC, LLC · 2023 · $249,999 — ABSTRACT In this Phase I SBIR application, we propose to develop an intranasal, parainfluenza virus 5 (PIV5)-based human metapneumovirus (HMPV) vaccine. HMPV is one of the leading causes of acute respiratory infections (ARIs) in children, immunocompromised individuals, and the elderly. Illness range…
Kenneth A Matreyek · CASE WESTERN RESERVE UNIVERSITY · 2023 · $241,500 — PROJECT SUMMARY Viral spillover from animal reservoirs into humans can decimate public health systems and cripple the world economy, as evident with the current SARS-CoV-2 pandemic. Continued wildlife habitat destruction, human expansion, and routine global travel keep increasing the likelihood tha…
RONALD N HARTY · FOX CHASE CHEMICAL DIVERSITY CENTER, INC · 2023 · $292,428 — The ultimate goal of this Phase I application is to discover and develop host-oriented small molecule compounds targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 is a novel coronavirus driving the current global pandemic of severe respiratory syndrome in hu…
Dan Jane-Wit · YALE UNIVERSITY · 2023 · $251,250 — PROJECT SUMMARY During severe COVID-19, immune hyperactivation contributes to tissue injury and worsened patient outcomes. Complement (C’) proteins are believed to centrally mediate COVID-19-related immune hyperactivation. C’ are a conserved set of immune proteins involved in host defense that beco…
Mary Catherine Cambou · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2023 · $203,580 — PROJECT SUMMARY/ABSTRACT While the clinical spectrum of SARS-CoV-2 infection in pregnancy ranges from asymptomatic to critical disease, pregnancy itself augments the risk of severe and critical COVID-19. The leading obstetrical societies in the U.S. recommend COVID-19 messenger RNA (mRNA) vaccinatio…
Samantha Kathleen Zepeda · UNIVERSITY OF WASHINGTON · 2023 · $43,033 — Abstract The outbreak of SARS-CoV-2 in late 2019 has resulted in the loss of over 6 million lives worldwide. Since then, there has been an intense focus on the development of vaccines and clinical treatments to increase the survivability of the disease caused by this virus. However, in nature other …
MICHAEL DAVID ALPERT · EMMUNE, INC · 2023 · $1,000,000 — We are developing vaccine antigens for SARS-CoV-2 that focus the antibody response onto neutralizing epitopes in the receptor binding domain (RBD) of the viral Spike (S) protein. Booster antigens derived from variants of SARS-CoV-2 would especially benefit from being limited to the RBD, due to the p…
Richard Dean Braatz · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2023 · $500,000 — Project Summary: A modular platform for rapid VLP vaccine development and manufacturing for SARS-CoV-2 pandemic response This proposal aims to design, develop, and manufacture a virus-like particle (VLP) vaccine for SARS-CoV-2, and the techniques developed throughout the work can be applied to accel…
SANKAR ADHYA · DIVISION OF BASIC SCIENCES - NCI · 2023 · $1,110,488 — Part A. Three lines of investigations are being pursued currently. 1. Use of bacteriophages in treating human diseases because of bacterial infections. We are currently dealing with infections caused by Klebsiella. We have succeeded in defining bacteriophage cocktails that take care of bacteriophage…